HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome

Simona Di Martino, Carla Azzurra Amoreo, Barbara Nuvoli, Rossella Galati, Sabrina Strano, Francesco Facciolo, Gabriele Alessandrini, Harvey I. Pass, Gennaro Ciliberto, Giovanni Blandino, Ruggero De Maria, Mario Cioce

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Adaptive resistance to therapy is a hallmark of cancer progression. To date, it is not entirely clear how microenvironmental stimuli would mediate emergence of therapy-resistant cell subpopulations, although a rearrangement of the cancer cell secretome following therapy-induced stress can be pivotal for such a process. Here, by using the highly chemoresistant malignant pleural mesothelioma (MPM) as an experimental model, we unveiled a key contribution of the chaperone HSP90 at assisting a chemotherapy-instigated Senescence-Associated-Secretory-Phenotype (SASP). Thus, administration of a clinical trial grade, HSP90, inhibitor blunted the release of several cytokines by the chemotherapy-treated MPM cells, including interleukin (IL)-8. Reduction of IL-8 levels hampered the FAK-AKT signaling and inhibited 3D growth and migration. This correlated with downregulation of key EMT and chemoresistance genes and affected the survival of chemoresistant ALDHbright cell subpopulations. Altogether, inhibition of HSP90 provoked a switch from a pro-tumorigenic SASP to a pro-apoptotic senescence status, thus resulting in chemosensitizing effects. In mouse xenografts treated with firstline agents, inhibiting HSP90 blunted FAK activation and reduced the expression of ALDH1A3 and the levels of circulating human IL-8, these latter strongly correlating with the effect on tumor growth. We validated the above findings in primary mesothelioma cultures, a more clinically relevant model. We unveiled here a key contribution of the chaperone HSP90 at assisting the secretory stress in chemotherapy-treated cells, which may warrant further investigation in combinatorial therapeutic settings.

Original languageEnglish
Pages (from-to)1369-1385
Number of pages17
JournalOncogene
Volume37
Issue number10
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Interleukin-8
Drug Therapy
Phenotype
Neoplasms
Mesothelioma
Growth
Cell- and Tissue-Based Therapy
Heterografts
Theoretical Models
Therapeutics
Down-Regulation
Clinical Trials
Cytokines
Genes
Malignant Mesothelioma

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. / Di Martino, Simona; Amoreo, Carla Azzurra; Nuvoli, Barbara; Galati, Rossella; Strano, Sabrina; Facciolo, Francesco; Alessandrini, Gabriele; Pass, Harvey I.; Ciliberto, Gennaro; Blandino, Giovanni; De Maria, Ruggero; Cioce, Mario.

In: Oncogene, Vol. 37, No. 10, 01.03.2018, p. 1369-1385.

Research output: Contribution to journalArticle

@article{0521eca6edaf428190c38f958787d70e,
title = "HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome",
abstract = "Adaptive resistance to therapy is a hallmark of cancer progression. To date, it is not entirely clear how microenvironmental stimuli would mediate emergence of therapy-resistant cell subpopulations, although a rearrangement of the cancer cell secretome following therapy-induced stress can be pivotal for such a process. Here, by using the highly chemoresistant malignant pleural mesothelioma (MPM) as an experimental model, we unveiled a key contribution of the chaperone HSP90 at assisting a chemotherapy-instigated Senescence-Associated-Secretory-Phenotype (SASP). Thus, administration of a clinical trial grade, HSP90, inhibitor blunted the release of several cytokines by the chemotherapy-treated MPM cells, including interleukin (IL)-8. Reduction of IL-8 levels hampered the FAK-AKT signaling and inhibited 3D growth and migration. This correlated with downregulation of key EMT and chemoresistance genes and affected the survival of chemoresistant ALDHbright cell subpopulations. Altogether, inhibition of HSP90 provoked a switch from a pro-tumorigenic SASP to a pro-apoptotic senescence status, thus resulting in chemosensitizing effects. In mouse xenografts treated with firstline agents, inhibiting HSP90 blunted FAK activation and reduced the expression of ALDH1A3 and the levels of circulating human IL-8, these latter strongly correlating with the effect on tumor growth. We validated the above findings in primary mesothelioma cultures, a more clinically relevant model. We unveiled here a key contribution of the chaperone HSP90 at assisting the secretory stress in chemotherapy-treated cells, which may warrant further investigation in combinatorial therapeutic settings.",
author = "{Di Martino}, Simona and Amoreo, {Carla Azzurra} and Barbara Nuvoli and Rossella Galati and Sabrina Strano and Francesco Facciolo and Gabriele Alessandrini and Pass, {Harvey I.} and Gennaro Ciliberto and Giovanni Blandino and {De Maria}, Ruggero and Mario Cioce",
year = "2018",
month = "3",
day = "1",
doi = "10.1038/s41388-017-0044-8",
language = "English",
volume = "37",
pages = "1369--1385",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome

AU - Di Martino, Simona

AU - Amoreo, Carla Azzurra

AU - Nuvoli, Barbara

AU - Galati, Rossella

AU - Strano, Sabrina

AU - Facciolo, Francesco

AU - Alessandrini, Gabriele

AU - Pass, Harvey I.

AU - Ciliberto, Gennaro

AU - Blandino, Giovanni

AU - De Maria, Ruggero

AU - Cioce, Mario

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Adaptive resistance to therapy is a hallmark of cancer progression. To date, it is not entirely clear how microenvironmental stimuli would mediate emergence of therapy-resistant cell subpopulations, although a rearrangement of the cancer cell secretome following therapy-induced stress can be pivotal for such a process. Here, by using the highly chemoresistant malignant pleural mesothelioma (MPM) as an experimental model, we unveiled a key contribution of the chaperone HSP90 at assisting a chemotherapy-instigated Senescence-Associated-Secretory-Phenotype (SASP). Thus, administration of a clinical trial grade, HSP90, inhibitor blunted the release of several cytokines by the chemotherapy-treated MPM cells, including interleukin (IL)-8. Reduction of IL-8 levels hampered the FAK-AKT signaling and inhibited 3D growth and migration. This correlated with downregulation of key EMT and chemoresistance genes and affected the survival of chemoresistant ALDHbright cell subpopulations. Altogether, inhibition of HSP90 provoked a switch from a pro-tumorigenic SASP to a pro-apoptotic senescence status, thus resulting in chemosensitizing effects. In mouse xenografts treated with firstline agents, inhibiting HSP90 blunted FAK activation and reduced the expression of ALDH1A3 and the levels of circulating human IL-8, these latter strongly correlating with the effect on tumor growth. We validated the above findings in primary mesothelioma cultures, a more clinically relevant model. We unveiled here a key contribution of the chaperone HSP90 at assisting the secretory stress in chemotherapy-treated cells, which may warrant further investigation in combinatorial therapeutic settings.

AB - Adaptive resistance to therapy is a hallmark of cancer progression. To date, it is not entirely clear how microenvironmental stimuli would mediate emergence of therapy-resistant cell subpopulations, although a rearrangement of the cancer cell secretome following therapy-induced stress can be pivotal for such a process. Here, by using the highly chemoresistant malignant pleural mesothelioma (MPM) as an experimental model, we unveiled a key contribution of the chaperone HSP90 at assisting a chemotherapy-instigated Senescence-Associated-Secretory-Phenotype (SASP). Thus, administration of a clinical trial grade, HSP90, inhibitor blunted the release of several cytokines by the chemotherapy-treated MPM cells, including interleukin (IL)-8. Reduction of IL-8 levels hampered the FAK-AKT signaling and inhibited 3D growth and migration. This correlated with downregulation of key EMT and chemoresistance genes and affected the survival of chemoresistant ALDHbright cell subpopulations. Altogether, inhibition of HSP90 provoked a switch from a pro-tumorigenic SASP to a pro-apoptotic senescence status, thus resulting in chemosensitizing effects. In mouse xenografts treated with firstline agents, inhibiting HSP90 blunted FAK activation and reduced the expression of ALDH1A3 and the levels of circulating human IL-8, these latter strongly correlating with the effect on tumor growth. We validated the above findings in primary mesothelioma cultures, a more clinically relevant model. We unveiled here a key contribution of the chaperone HSP90 at assisting the secretory stress in chemotherapy-treated cells, which may warrant further investigation in combinatorial therapeutic settings.

UR - http://www.scopus.com/inward/record.url?scp=85047751334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047751334&partnerID=8YFLogxK

U2 - 10.1038/s41388-017-0044-8

DO - 10.1038/s41388-017-0044-8

M3 - Article

AN - SCOPUS:85047751334

VL - 37

SP - 1369

EP - 1385

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 10

ER -